Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 2/2022

01-04-2022 | Fatty Liver | Correction

Correction to: The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study

Authors: Yu-Guang Chen, Chih-Wei Yang, Chi-Hsiang Chung, Ching-Liang Ho, Wei-Liang Chen, Wu-Chien Chien

Published in: Hepatology International | Issue 2/2022

Login to get access

Excerpt

The above article was published with few incorrected sentences we did not find before. …
Metadata
Title
Correction to: The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study
Authors
Yu-Guang Chen
Chih-Wei Yang
Chi-Hsiang Chung
Ching-Liang Ho
Wei-Liang Chen
Wu-Chien Chien
Publication date
01-04-2022
Publisher
Springer India
Keyword
Fatty Liver
Published in
Hepatology International / Issue 2/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-022-10308-9

Other articles of this Issue 2/2022

Hepatology International 2/2022 Go to the issue

Letter to the Editor

Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?

Editorial

Is lean non-alcoholic fatty liver disease a distinct entity?

Original Article

Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank

Original Article

Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial

Review Article

Management of hepatitis B virus reactivation due to treatment of COVID-19

Original Article

MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits